# ALZN catalysts: Alzamend Neuro, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/alzn/catalysts

> Alzamend Neuro, Inc. (ALZN) has no upcoming catalysts in this calendar. The latest recorded is the latozinemab topline data readout, Q4 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ALZN?

Alzamend Neuro, Inc. (ALZN) has no upcoming catalysts in this calendar. The latest recorded is the latozinemab topline data readout, Q4 2026. SEC Form 10-Q: "In March 2026, we announced the initiation of the Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with BD and expect to report topline data in the fourth quarter of 2026." [Calendar and source filings](https://sec-api.dev/companies/alzn/catalysts)

Source: SEC Form 10-Q, accession 0001214659-26-011572, https://www.sec.gov/Archives/edgar/data/1677077/000121465926011572/alz9226210q.htm (retrieved 2026-11-12). Last confirmed 2026-09-10. Cite: https://sec-api.dev/companies/alzn/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Alzamend Neuro, Inc. |
| Ticker | ALZN (Nasdaq) |
| SEC CIK | 1677077 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/alzn |

## Cash runway

Cash $7.6M as of 2026-07-31; quarterly burn $1.1M; about 20.0 months of runway at that rate (XBRL company facts, accession 0001214659-26-011572).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2022 | [Latozinemab trial start](https://sec-api.dev/pdufa/latozinemab) | ALZN |  | completed | "We completed our Phase I clinical trial in March 2022 and initiated a Phase IIA Multiple Ascending Dose ("MAD") clinical trial in May 2022." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1677077/000121465925010763/u7925110k.htm)) |
| Mar 2023 | [Latozinemab topline data readout](https://sec-api.dev/pdufa/latozinemab) | ALZN |  | completed, positive | "We completed the Phase IIA clinical trial in March 2023, announced positive topline data in June 2023 and announced full data sets in October 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1677077/000121465926008832/az72426110k.htm)) |
| Apr 2023 | [ALZN002 trial start](https://sec-api.dev/pdufa/alzn002) | ALZN |  | completed | "In April 2023, we initiated a Phase I/IIA clinical trial for ALZN002 to evaluate its safety, tolerability, and efficacy in 20-30 patients with mild to moderate Alzheimer's, comparing multiple ascending doses to a placebo." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1677077/000121465925010830/ex99_1.htm)) |
| Jun 2023 | [Alzamend Neuro, Inc. topline data readout](https://sec-api.dev/companies/alzn/catalysts) | ALZN |  | completed, positive | "2023 and announced positive topline data in June 2023." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1677077/000121465926011572/alz9226210q.htm)) |
| December 12, 2024 | [Alzamend Neuro, Inc. earnings report](https://sec-api.dev/companies/alzn/catalysts) | ALZN |  | completed | "Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), reported its financial results for the second quarter ended October 31, 2024, which were disclosed on a quarterly report on Form 10-Q filed on December" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1677077/000121465924020439/ex99_1.htm)) |
| Jul 2025 | [Latozinemab trial start](https://sec-api.dev/pdufa/latozinemab) | ALZN |  | completed | "In July 2025, the Company initiated its Phase II clinical trial of AL001 in patients with BD." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1677077/000121465926008832/az72426110k.htm)) |
| July 23, 2025 | [Alzamend Neuro, Inc. earnings report](https://sec-api.dev/companies/alzn/catalysts) | ALZN |  | completed | "Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), reported its financial results for the year ended April 30, 2025, which were disclosed on an annual report on Form 10-K filed on July 22, 2025, with the Securities and Exchange Commission." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1677077/000121465925010830/ex99_1.htm)) |
| Q1 2026 | [Alzamend Neuro, Inc. topline data readout](https://sec-api.dev/companies/alzn/catalysts) | ALZN |  | scheduled | "In November 2025, we announced that we completed the clinical portion of the Phase II study in healthy human subjects and expect to report topline data in the first quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1677077/000121465926003166/z3626110q.htm)) |
| Mar 2026 | [Lithobid® (lithium) topline data readout](https://sec-api.dev/pdufa/lithium) | ALZN |  | scheduled | "We expect to present topline data from this study by the end of March 2026." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1677077/000121465926002941/i36260424b5.htm)) |
| Q4 2026 | [Latozinemab trial start](https://sec-api.dev/pdufa/latozinemab) | ALZN |  | scheduled | "In March 2026, we announced the initiation of the Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with BD and expect to report topline data in the fourth quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1677077/000121465926011572/alz9226210q.htm)) |
| Q4 2026 | [Latozinemab topline data readout](https://sec-api.dev/pdufa/latozinemab) | ALZN |  | scheduled | "In March 2026, we announced the initiation of the Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with BD and expect to report topline data in the fourth quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1677077/000121465926011572/alz9226210q.htm)) |

## Drugs

- [ALZN002](https://sec-api.dev/pdufa/alzn002): 
- [Lithobid® (lithium)](https://sec-api.dev/pdufa/lithium): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/alzn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ALZN catalysts: Alzamend Neuro, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/alzn/catalysts

```bibtex
@misc{secapidev_companies_alzn_catalysts_20261116,
  title        = {ALZN catalysts: Alzamend Neuro, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/alzn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_alzn_catalysts_20261116","title":"ALZN catalysts: Alzamend Neuro, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/alzn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
